Thursday, January 02, 2020 2:15:23 PM
I accumulated the bulk of my position during the weakness the stock saw during 2018 tax loss selling under $0.05 and didn't put a single share up for sale during this recent spike to $1 because I believe these could be worth multiples more than $1 in a few years, once Flurpiridaz is approved and gives cardiac PET a clear advantage over SPECT (with it's clinical trial's last patient follow-up expected in August 2020) and good execution by Positron in making the most cost effective scanners for small and medium cardiac practices.
I'll continue to accumulate on any weakness, but hope to see the company begin to catch up with filings and relisting soon, so that we can watch their growth story begin to unfold over the next few years in public filings.
"Our houses are such unwieldy property that we are often imprisoned rather than housed in them." - Henry David Thoreau, Walden: Economy, 1854
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM